Solid Carcinoma
Conditions
Keywords
cancer, immunomonitoring, CD247 -zeta chain, chronic inflamation, anticancertherapy
Brief summary
Tumors have a systemic immune modifying effect. They affect the immune system similarly to states of chronic inflammation and these effects can: * be monitored through analysis of nk t and myeloid cells mainly through studies of the zeta chain but also through other means * may be decreased following effective anticancer therapy - may even be used to study the effectiveness of anticancer therapy * are important to monitor if the investigators plan on formulation of systemic immune therapy Thus immumonitoring of systemic blood cells may turn out to be an important prognostic and predictive factor in many cancer types
Detailed description
CD247 Known also as the zeta chain is important for relaying T-cell induced signal transduction. Interestingly studies by Baniash and others have demonstrated that this chain is down regulated in states of chronic inflammation and cancer in peripheral blood T cells and also in NK cells However there has not been a prospective study of this marker in cancer and control patients such a study will reveal not only the levels of CD247 in immune cells of cancer patients compared to controls but may reveal the effect of anticancer therapies on CD247 in cancer patients such a study may contribute significantly to our ability to monitor systemic immune system characteristics in cancer patients and help in any further studies of immunomodulation such as vaccination schemes in such patients
Interventions
None listed
Sponsors
Hebrew University of Jerusalem
Hadassah Medical Organization
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* patients with cancer or blood donators agreeing to participate in the trial
Exclusion criteria
* other disease states which may cause chronic inflammation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| changes in immune markers mainly cd247-zeta chain - levels in cancer patients undergoing therapy | 4-2013 24 month | Hopefully by this time the investigators will be able to see if there are lower zeta chain intracellular expression levels in cancer patients and whether response to therapy enhances recovery of zeta chain |
| levels of zeta chain -cd247 in cancer patients | till begining of 2013 ( putative) | intracellular levels of cd247 compared to other intracellular proteins and other markers of immune response will be monitored in patients with cancer and a control group in cancer patients the investigators will conduct several tests to analyze effects of therapy |
Countries
Israel
Contacts
Primary ContactHovav Nechushtan, MD PHD
Backup ContactMoshe sade, BSC
Outcome results
None listed